It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HSIC’s FA Score shows that 0 FA rating(s) are green whileZYXI’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HSIC’s TA Score shows that 5 TA indicator(s) are bullish while ZYXI’s TA Score has 5 bullish TA indicator(s).
HSIC (@Medical Distributors) experienced а -4.10% price change this week, while ZYXI (@Medical Distributors) price change was -13.65% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was -1.08%. For the same industry, the average monthly price growth was -0.26%, and the average quarterly price growth was -3.44%.
HSIC is expected to report earnings on Aug 05, 2025.
ZYXI is expected to report earnings on Jul 24, 2025.
Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
HSIC | ZYXI | HSIC / ZYXI | |
Capitalization | 9.71B | 398M | 2,438% |
EBITDA | 877M | 17.9M | 4,899% |
Gain YTD | 1.720 | -73.159 | -2% |
P/E Ratio | 23.50 | 46.30 | 51% |
Revenue | 12.3B | 184M | 6,685% |
Total Cash | 171M | 44.6M | 383% |
Total Debt | 2.74B | 76.2M | 3,597% |
HSIC | ZYXI | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 64 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 93 Overvalued | |
PROFIT vs RISK RATING 1..100 | 59 | 100 | |
SMR RATING 1..100 | 62 | 93 | |
PRICE GROWTH RATING 1..100 | 51 | 96 | |
P/E GROWTH RATING 1..100 | 62 | 92 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
HSIC's Valuation (78) in the Medical Distributors industry is in the same range as ZYXI (93) in the Medical Specialties industry. This means that HSIC’s stock grew similarly to ZYXI’s over the last 12 months.
HSIC's Profit vs Risk Rating (59) in the Medical Distributors industry is somewhat better than the same rating for ZYXI (100) in the Medical Specialties industry. This means that HSIC’s stock grew somewhat faster than ZYXI’s over the last 12 months.
HSIC's SMR Rating (62) in the Medical Distributors industry is in the same range as ZYXI (93) in the Medical Specialties industry. This means that HSIC’s stock grew similarly to ZYXI’s over the last 12 months.
HSIC's Price Growth Rating (51) in the Medical Distributors industry is somewhat better than the same rating for ZYXI (96) in the Medical Specialties industry. This means that HSIC’s stock grew somewhat faster than ZYXI’s over the last 12 months.
HSIC's P/E Growth Rating (62) in the Medical Distributors industry is in the same range as ZYXI (92) in the Medical Specialties industry. This means that HSIC’s stock grew similarly to ZYXI’s over the last 12 months.
HSIC | ZYXI | |
---|---|---|
RSI ODDS (%) | 1 day ago65% | 2 days ago86% |
Stochastic ODDS (%) | 1 day ago53% | 1 day ago72% |
Momentum ODDS (%) | 1 day ago56% | 1 day ago86% |
MACD ODDS (%) | 1 day ago58% | N/A |
TrendWeek ODDS (%) | 1 day ago57% | 1 day ago82% |
TrendMonth ODDS (%) | 1 day ago47% | 1 day ago80% |
Advances ODDS (%) | 20 days ago54% | 1 day ago76% |
Declines ODDS (%) | 3 days ago56% | 3 days ago81% |
BollingerBands ODDS (%) | 1 day ago60% | 1 day ago74% |
Aroon ODDS (%) | 1 day ago45% | 1 day ago77% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
QMOM | 62.71 | 0.49 | +0.79% |
Alpha Architect US Quantitative Momt ETF | |||
SPHQ | 71.08 | 0.15 | +0.21% |
Invesco S&P 500® Quality ETF | |||
APRH | 24.94 | 0.05 | +0.20% |
Innovator Premium Income 20 Bar ETF -Apr | |||
DWUS | 50.01 | -0.26 | -0.51% |
AdvisorShares DW FSM US Core ETF | |||
ETW | 8.40 | -0.05 | -0.59% |
Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund |
A.I.dvisor tells us that ZYXI and HSIC have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ZYXI and HSIC's prices will move in lockstep.
Ticker / NAME | Correlation To ZYXI | 1D Price Change % | ||
---|---|---|---|---|
ZYXI | 100% | +0.47% | ||
HSIC - ZYXI | 26% Poorly correlated | -0.26% | ||
OMI - ZYXI | 17% Poorly correlated | -0.45% | ||
GEG - ZYXI | 11% Poorly correlated | +0.23% | ||
AMFPF - ZYXI | 10% Poorly correlated | +8.31% | ||
EDAP - ZYXI | 9% Poorly correlated | +0.84% | ||
More |